About Seres Therapeutics
Seres Therapeutics is a company based in Cambridge (United States) founded in 2010 by David Berry. Seres Therapeutics has raised $257.13 million across 9 funding rounds from investors including ARE, Flagship Pioneering and Nestlé Health Science. The company has 103 employees as of December 31, 2024. Seres Therapeutics offers products and services including Live Biotherapeutics and GoodNature Program. Seres Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, UCB, Grifols and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 103 as on 31 Dec, 2024
- Founders David Berry
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Seres Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$146.57 M (USD)-28.88as on Dec 31, 2024
-
EBITDA
-$103.35 M (USD)42.58as on Dec 31, 2024
-
Total Equity Funding
$257.13 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
ARE
& 6 more
-
Employee Count
103
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Seres Therapeutics
Seres Therapeutics is a publicly listed company on the NASDAQ with ticker symbol MCRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Seres Therapeutics
Seres Therapeutics offers a comprehensive portfolio of products and services, including Live Biotherapeutics and GoodNature Program.
Treats bacterial infections and GI diseases through innovative biotherapeutics.
Facilitates stool donations for biotherapeutics research and development.
People of Seres Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
19 people
Software Development Team
15 people
Scientific Team
6 people
Product Management Team
6 people
Operations Team
5 people
Senior Team
5 people
Board Team
4 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Seres Therapeutics
Seres Therapeutics has successfully raised a total of $257.13M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Seres Therapeutics
Seres Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Flagship Pioneering and Nestlé Health Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Seres Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Seres Therapeutics
Investment portfolio details for Seres Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Seres Therapeutics
Detailed financials for Seres Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Seres Therapeutics Comparisons
Peer comparison for Seres Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Seres Therapeutics
Seres Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, UCB, Grifols and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
Detailed competitors of Seres Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Seres Therapeutics
Complete news archive for Seres Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seres Therapeutics
Seres Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Seres Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Seres Therapeutics is a funded company, having raised a total of $257.13M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Seres Therapeutics is 103.
Seres Therapeutics was founded in 2010 and is based in Cambridge, United States. Operations center on the biotechnology sector, where microbiome-based therapeutics are created for treating conditions such as C. difficile infection, antibiotic-resistant infections, graft-versus-host disease, and ulcerative colitis. The pipeline includes candidates like SER-109, SER-155, and SER-287, with development focused on clinical advancement and therapeutic applications.
Seres Therapeutics's top competitors include Kymeratx, PureTech Health and Poseida Therapeutics.
Seres Therapeutics offers Live Biotherapeutics and GoodNature Program.
Yes, Seres Therapeutics is publicly traded on NASDAQ under the ticker symbol MCRB.
Seres Therapeutics has 7 investors. Key investors include ARE, Flagship Pioneering, Nestlé Health Science, CARB-X, and Ludicrous Ventures.
The ticker symbol of Seres Therapeutics is MCRB on NASDAQ.